logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Sectors
DMAC
DiaMedica Therapeutics Inc.
7.03
1 x 6.63
1 x 7.28
bid
ask
-
0.05
0.71%
04:00 PM
timesize
Ytd-11.68%
1y52.83%
7.02
day range
7.07
4.01
52 week range
10.42
Open7.07Prev Close7.08Low7.02High7.07Mkt Cap381.49M
Vol4.55KAvg Vol201.36KEPS-0.71P/E-9.97Forward P/E-7.26
Beta0.97Short Ratio3.88Inst. Own31.61%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning05-0650-d Avg6.42200-d Avg7.211yr Est7.00

DMAC News

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma

Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
benzinga.com
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol

DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
gurufocus.com
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing no
benzinga.com
DiaMedica Therapeutics Doses First Patients In Its Phase 2 Trial Of DM199 For The Treatment Of Fetal

First clinical evaluation of DM199 (rinvecalinase alfa) in fetal growth restriction, a leading cause

DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
businesswire.com
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma

DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
businesswire.com
DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma

DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026
businesswire.com
DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma

DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
businesswire.com
DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma

DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
businesswire.com
DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma

DiaMedica Therapeutics Inc. (DMAC) Q1 2026 Earnings Call Transcript
seekingalpha.com
DiaMedica Therapeutics Inc. (DMAC) Q1 2026 Earnings Call Transcript

DiaMedica Therapeutics Inc. (DMAC) Q1 2026 Earnings Call Transcript

Earnings Scheduled For May 6, 2026
benzinga.com
Earnings Scheduled For May 6, 2026

DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
businesswire.com
DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma

DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026
businesswire.com
DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma

DiaMedica Therapeutics Highlights DM199 Preeclampsia Data, Stroke Interim Catalyst at RedChip Conference
defenseworld.net
DiaMedica Therapeutics Highlights DM199 Preeclampsia Data, Stroke Interim Catalyst at RedChip Confer

DiaMedica Therapeutics (NASDAQ: DMAC) President and CEO Rick Pauls outlined the company's developmen

DiaMedica Therapeutics Inc. (DMAC) Q4 2025 Earnings Call Transcript
seekingalpha.com
DiaMedica Therapeutics Inc. (DMAC) Q4 2025 Earnings Call Transcript

DiaMedica Therapeutics Inc. (DMAC) Q4 2025 Earnings Call Transcript

DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
businesswire.com
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma

Earnings Scheduled For March 30, 2026
benzinga.com
Earnings Scheduled For March 30, 2026

Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings
benzinga.com
Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) will release earnings for its fourth quarter after the cl

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Average Rating of “Moderate Buy” by Brokerages
defenseworld.net
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Average Rating of “Moderate Buy” by Brokerages

Shares of DiaMedica Therapeutics, Inc. (NASDAQ: DMAC - Get Free Report) have received a consensus ra

DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026
businesswire.com
DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma

DiaMedica Therapeutics (DMAC) Expected to Announce Earnings on Monday
defenseworld.net
DiaMedica Therapeutics (DMAC) Expected to Announce Earnings on Monday

DiaMedica Therapeutics (NASDAQ: DMAC - Get Free Report) is expected to be releasing its Q4 2025 resu

Brokerages Set DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Target Price at $12.33
defenseworld.net
Brokerages Set DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Target Price at $12.33

DiaMedica Therapeutics, Inc. (NASDAQ: DMAC - Get Free Report) has earned a consensus rating of "Mode

DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia
businesswire.com
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preecl

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma

DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences
businesswire.com
DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma

12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

Earnings Scheduled For November 12, 2025
benzinga.com
Earnings Scheduled For November 12, 2025
benzinga.com
Earnings Scheduled For August 12, 2025
benzinga.com
Earnings Scheduled For May 13, 2025
benzinga.com
Earnings Scheduled For March 17, 2025
benzinga.com
Earnings Scheduled For November 13, 2024
benzinga.com
Earnings Scheduled For August 14, 2023

Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report q